Abstract P2-13-03: KEYRICHED-1 - A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study with Pembrolizumab in Combination with Dual Anti-Her2 Blockade with Trastuzumab and Pertuzumab in Early Breast Cancer Patients with Molecular HER2-enriched Intrinsic Subtype